Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EmPATH: Empagliflozin in Pulmonary Arterial Hypertension
NCT06992440Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Jul 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in pulmonary arterial hypertension (PAH). Started Jun 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06992440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992440.